Physician profile
Leslie Gray
NPI 1720082084
$37,094.88
in general payments reported to CMS, 2019-2025
25 companies · $3,732 in 2025
The $3,732 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $715 · 2021: $5,453 · 2022: $6,685 · 2023: $14K · 2024: $5,397 · 2025: $3,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $3,166 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,863.41 |
| Food and Beverage | $3,166.04 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,879.08 | 2019-2025 | |
| Allergan, INC. | $11,577.94 | 2019-2023 | |
| Merz North America, INC. | $2,841.94 | 2019-2023 | |
| Genzyme Corporation | $339.86 | 2019-2025 | |
| Pfizer INC. | $314.86 | 2019-2024 | |
| Leo Pharma INC. | $277.92 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $166.92 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $116.40 | 2019-2025 | Nemluvio |
| Ucb, INC. | $107.53 | 2022-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $55.27 | 2022 | |
| Sun Pharmaceutical Industries INC. | $53.76 | 2021-2025 | Winlevi |
| Arcutis Biotherapeutics, INC. | $53.19 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $52.12 | 2022-2025 | |
| Almirall LLC | $43.80 | 2020-2023 | Seysara |
| Incyte Corporation | $35.33 | 2023-2025 | Opzelura |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $27.74 | 2022 | |
| Amgen INC. | $21.70 | 2025 | Otezla |
| Mayne Pharma Commercial LLC | $20.03 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.34 | 2021 | |
| Botanix Sb INC | $17.37 | 2025 | Sofdra |
| Lilly USA, LLC | $16.19 | 2022 | |
| Mission Pharmacal Company | $15.46 | 2019 | |
| Organon LLC | $14.67 | 2025 | |
| Aclaris Therapeutics, INC. | $13.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.51 | 2024 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.